This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Single Dose Monurol for Treatment of Acute Cystitis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Ann Stapleton, University of Washington
ClinicalTrials.gov Identifier:
NCT00976963
First received: September 11, 2009
Last updated: May 10, 2017
Last verified: May 2017
  Purpose

Urinary tract infecton (UTI) is a very common problem in young healthy women, afflicting approximately one-half of women by their late 20's. One of the most common antibiotics used to treat UTIs is Trimethoprim-sulfa (TMP-SMX), usually for total of three days. However, concerns about increased antibiotic resistance have led to increased interest in studying other antibiotics for UTI.

An alternative antibiotic which is also FDA approved for the treatment of UTIs is fosfomycin (Monurol). The effectiveness of fosfomycin in curing UTIs when given as a single dose is not well studied. The purpose of this research study is to determine what the cure rates are with a single dose of fosfomycin versus the more standard 3-day course of TMP-SMX.


Condition Intervention
Urinary Tract Infection Drug: Fosfomycin Drug: TMP/SMX DS

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Single Dose Monurol for Treatment of Acute Cystitis

Resource links provided by NLM:


Further study details as provided by Ann Stapleton, University of Washington:

Primary Outcome Measures:
  • To assess the efficacy of a single dose fosfomycin [ Time Frame: 28-30 post therapy ]

Secondary Outcome Measures:
  • To assess the tolerance of a single does of fosfomycin [ Time Frame: 28-30 days post therapy ]

Enrollment: 300
Study Start Date: September 2009
Estimated Study Completion Date: May 30, 2017
Primary Completion Date: November 29, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fosfomycin
Mix sachet with 1/2 glass cold water and stir. Drink immediatley
Drug: Fosfomycin
3g sachet single dose
Other Name: Monurol
Active Comparator: TMP/SMX
Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
Drug: TMP/SMX DS
160/800mg BID x 3 days
Other Name: Septra

Detailed Description:

Procedures subjects will undergo once they have read and signed the consent are:

Questions about their medical and sexual history and current symptoms of UTI. They will be asked to provide a urine and peri-urethral sample and then are randomly assigned to one of the two treatment groups.They will be given a sheet to record symptoms at home. They will be asked to return to the clinic in 5-8 and 28-30 days after completing antibiotic therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected at each visit.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Non pregnant women in good health with symptoms of acute cystitis for less than 7 days

Exclusion Criteria:

  • Pregnant, lactating, or not regularly contracepting
  • History of chronic conditions such as diabetes
  • Known anatomic abnormalities of the urinary tract
  • Use of prophylactic antibiotics
  • History of allergy or intolerance to any of the study drugs
  • Recent (> 2 weeks)exposure to oral or parenteral antimicrobial
  • History of UTI in previous 1 month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00976963

Locations
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Ann E. Stapleton, M.D. University of WA
  More Information

Responsible Party: Ann Stapleton, Professor, Medicine, Infectious Diseases, University of Washington
ClinicalTrials.gov Identifier: NCT00976963     History of Changes
Other Study ID Numbers: 34776
Study First Received: September 11, 2009
Last Updated: May 10, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Ann Stapleton, University of Washington:
UTI

Additional relevant MeSH terms:
Urinary Tract Infections
Cystitis
Infection
Urologic Diseases
Urinary Bladder Diseases
Fosfomycin
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on June 23, 2017